Emyria Specialist Granted Authorised Prescriber Status
Released
Released
Announcement PDF
Developing innovative treatments for
mental health & neurological conditions
ASX Announcement | 10 January 2024
Emyria’s Specialist Psychiatrist Granted Authorised Prescriber Status
in MDMA-Assisted Therapy for PTSD
HIGHLIGHTS
Emyria's key specialist has been granted "Authorised Prescriber" approval from the TGA
Authorisation reflects Emyria's dedication to mental health care under strict regulatory,
ethical, and safety standards
Achieving Authorised Prescriber status for MDMA-assisted therapy in PTSD care signifies a
strategic step towards expanding Emyria's service offerings
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on delivering and
developing new treatments for mental health and select neurological conditions, is pleased
to announce the Company’s distinguished psychiatry specialist has been granted
"Authorised Prescriber" status by the Therapeutic Goods Administration (TGA). The
authorisation enables the prescribing of MDMA according to an ethics committee endorsed
care model developed by Emyria 1 and within the strict regulatory framework established by
the TGA for the treatment of Post-Traumatic Stress Disorder (PTSD). 2
Dr. Michael Winlo, CEO and MD, commented: "This authorisation demonstrates Emyria’s
commitment to evaluating emerging treatments within the strict regulatory framework set
by the TGA.
Emyria’s expertise and track record in innovative clinical service development and
Real-World Data capture uniquely positions us to evaluate new therapeutic options in a safe
and responsible way. Achieving Authorised Prescriber status showcases Emyria's capacity
for impactful and responsible growth in the field of mental health treatments."
Initial focus on Post-Traumatic Stress Disorder (PTSD):
PTSD affects approximately 1 million Australians 3. With up to one third of patients failing to
benefit from conventional therapies, there is a growing need for more effective treatments.
MDMA-assisted therapy (MDMA-AT) is being evaluated as a treatment for PTSD and multiple
Phase 3 clinical trials have been conducted by MAPS in the USA. 4, 5
Emyria is currently studying MDMA-AT therapy for PTSD in an ethics-approved clinical trial
(EMDMA-001). Experience with the trial has informed a unique delivery model for Emyria’s
Authorised Prescriber program.
Emyria ASX Announcement | 10 Jan 2024
1
Authorised Prescribers must adhere to stringent TGA guidelines to ensure the highest level
of patient care and safety. The authorisation is part of Emyria’s broader commitment to
increasing options for mental health through robust clinical research and ethical practice.
A presentation explaining how the Authorised Prescriber milestone fits into Emyria’s
broader strategy will be available on the ASX platform.
Risks associated with the use of MDMA
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best
placed to assess the suitability of a new medication against a patient’s individual
circumstances and medical history before proceeding. Adverse effects of MDMA include
high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare
cases it can cause loss of consciousness or trigger seizures. Other side effects include
involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating
and muscle/joint stiffness. These effects are unlikely at low doses in the treatment regimens
used in psychedelic-assisted psychotherapy while appropriately managed in a controlled
environment with direct medical supervision.
References:
1.
See ASX release 30 October 2023
2.
https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-en
able-prescribing-authorised-psychiatrists
The availability of these products is subject to the safety and efficacy of the products being
tested through clinical trials. Emyria makes no representations or warranties as to the safety
or efficacy of the products or the products’ ability (or the ability of its key compounds) to be
used in the treatment of indications such as PTSD. There are currently no approved products
containing MDMA that the TGA has evaluated for quality, safety and efficacy. Consumers
should be aware that MDMA may cause side effects, as set out in the “Risks associated with
the use of MDMA” in this announcement.
3.
https://www.phoenixaustralia.org/news/ptsd-awareness-day-2022/
4.
Mitchell, J.M., et al. MDMA-assisted therapy for severe PTSD: Nat Med 27, 1025–1033 (2021)
5.
Mitchell, J.M., et al. MDMA-assisted therapy for moderate to severe PTSD: Nat Med (2023).
https://doi.org/10.1038/s41591-023-02565-4
This release has been approved by the Board of Emyria.
Emyria ASX Announcement | 10 Jan 2024
2
FOR FURTHER INFORMATION
Managing Director
Michael Winlo
+61 (0) 8 6559 2800
mwinlo@emyria.com
Media Contact
Haley Chartres
+61 (0) 423 139 163
haley@hck.digital
Corporate Advisor
Sufian Ahmed
+61 (0) 412 316 162
info@62capital.com.au
EMYRIA’S INTERACTIVE INVESTOR HUB
Investorhub.emyria.com Interact with Emyria’s announcements and updates
by asking questions and comments, which our team can respond to where possible.
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release
about future expectations, plans and prospects for the Company, the Company’s strategy, future
operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” and similar expressions, constitute forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various important
factors, including: the Company’s ability to successfully develop its product candidates and timely
complete its planned clinical programs and the Company’s ability to obtain marketing approvals for
its product candidates. In addition, the forward-looking statements included in this press release
represents the Company’s views as of the date hereof. The Company anticipates that subsequent
events and developments will cause the Company’s views to change. However, while the Company
may elect to update these forward-looking statements at some point in the future, the Company
specifically disclaims any obligation to do so. These forward-looking statements should not be relied
upon as representing the Company’s views as of any date subsequent to the date hereof.
Emyria ASX Announcement | 10 Jan 2024
3
Share your feedback
Discover